Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis.

Date publication

juin 2023

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Solitano V, Vuyyuru SK, MacDonald JK, Zayadi A, Parker CE, Narula N, Peyrin-Biroulet L, Danese S, Feagan BG, Singh S, Ma C, Jairath V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37317532

Résumé

Oral small-molecule drugs (SMDs) are expanding the therapeutic landscape for inflammatory bowel disease (IBD). This systematic review and meta-analysis summarises the efficacy and safety of JAK inhibitor (JAKi) and sphingosine-1-phosphate (S1P) receptor modulator treatments for ulcerative colitis (UC) and Crohn's disease (CD).

Mots clés

Inflammatory bowel disease, JAK inhibitors, S1P receptor modulators

Référence

J Crohns Colitis. 2023 06 15;: